{"i": ["DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine"], "o": []}
{"i": [], "o": []}
{"i": ["DNA prime - recombinant adenovirus 5 ( rAd5 ) boost HIV vaccine"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["ART intensification", "six plasmid DNA prime ( envA , envB , envC , gagB , polB , nefB ) and rAd5 boost HIV vaccine"], "o": []}
{"i": [], "o": ["Antibody binding levels"]}
{"i": [], "o": ["neutralization efficiency and antibody - dependent cellular cytotoxicity ( ADCC )."]}
{"i": ["DNA prime - rAd5 boost vaccine"], "o": ["cross - clade HIV - specific antibody response"]}
{"i": [], "o": ["antibody binding levels", "neutralization or ADCC responses ."]}
{"i": [], "o": ["total CD4 + cell associated HIV DNA"]}
{"i": [], "o": []}
{"i": ["Antiretroviral therapy ( ART )"], "o": []}
{"i": [], "o": ["latent viral reservoir"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["HIV - specific antibodies", "HIV disease progression", "CD8 + T cell responses"]}
{"i": [], "o": []}
{"i": ["ALVAC - HIV and AIDSVAX B / E ( gp120 ) vaccine"], "o": ["HIV - specific antibody - dependent cellular cytotoxicity ( ADCC ) responses", "cytotoxic T - lymphocyte responses"]}
{"i": [], "o": ["HIV acquisition", "risk of HIV infection", "ADCC IgG"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["antibody response"]}
{"i": ["HIV DNA vaccine"], "o": ["immunogenicity", "CD4 + and CD8 + IFN - \u03b3 ELISpot responses", "HIV - specific antibody responses"]}
{"i": ["HIV DNA prime - rAd5 boost vaccine ( containing VRC - HIVDNA016 - 00 - VP and VRC - HIVADV014 - 00 - VP"], "o": ["binding to peptides", "pooled clade A , B , or C envelope antibody titers"]}
{"i": [], "o": ["antibody neutralization or ADCC ."]}
{"i": ["HIV DNA prime and rAd5 boost vaccine"], "o": ["HIV - specific antibody titer , neutralization , and ADCC"]}
{"i": [], "o": []}
{"i": ["ART intensification", "DNA prime - rAd5 boost vaccination"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["raltegravir"], "o": []}
{"i": ["maraviroc"], "o": []}
{"i": ["VRC - HIVDNA016 - 00 - VP priming ( DNA prime , consisting of envA , envB , envC , gagB , polB , nefB ) vaccinations", "RAL / MVC / vaccine", "envA , envB , envC , gagB , polB , nefB )", "VRC - HIVADV014 - 00 - VP ( rAd5 boost"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["VRC - HIVDNA016 - 00 - VP", "VRC - HIVADV014 - 00 - VP .", "needle and syringe", "Biojector 2000 injection system"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["biotin - SP"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Virus production"]}
{"i": ["HIV - 1 Env - deleted backbone plasmid pSG3\u0394Env ( NIHARRRP", "HIV Env or VSV - g complementation plasmid using polyethyleneimine ( PEI )"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["TZM - bl reporter cells ( ATCC , PTA - 5659 )"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Luminescence in relative light units ( RLU )"]}
{"i": [], "o": []}
{"i": [], "o": ["virus neutralization"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["intracellular protease activity ( dead cell protease )"]}
{"i": [], "o": ["Percent cytotoxicity", "cytotoxicity"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["neutralization ( IC50 ) values and ADCC activity ."]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["suppressive ART"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["HIV RNA levels"]}
{"i": [], "o": ["median baseline CD4 + cell count", "median baseline total cell - associated HIV DNA", "median nadir CD4 + cell count"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["ART = antiretroviral therapy"], "o": []}
{"i": ["nucleoside"], "o": []}
{"i": ["NNRTI = non - nucleoside reverse transcriptase inhibitor"], "o": []}
{"i": ["ritonavir ."], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["NRTI + NNRTI + PI / r", "NNRTI", "NNRTI + PI"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["HIV - rAd5 boost"], "o": ["cross clade HIV - 1 specific antibody binding signals"]}
{"i": [], "o": ["signal intensity"]}
{"i": [], "o": ["Antibody - binding signals"]}
{"i": [], "o": []}
{"i": [], "o": ["antibody - binding signals"]}
{"i": [], "o": ["signal intensities against EnvA"]}
{"i": [], "o": ["signal intensities"]}
{"i": [], "o": []}
{"i": [], "o": ["signal intensity"]}
{"i": [], "o": ["antibody signal levels"]}
{"i": [], "o": ["antibody signals"]}
{"i": [], "o": ["EnvB antibody signal intensities"]}
{"i": [], "o": ["signal intensities", "EnvC - specific antibody signal intensities"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["IC50"]}
{"i": [], "o": ["IC50 values"]}
{"i": [], "o": []}
{"i": [], "o": ["IC50 values"]}
{"i": [], "o": ["IC50 values"]}
{"i": [], "o": ["IC50 values"]}
{"i": [], "o": ["IC50", "neutralization potency"]}
{"i": [], "o": ["Tier 2 neutralization"]}
{"i": [], "o": ["potency"]}
{"i": [], "o": []}
{"i": [], "o": ["neutralization potency"]}
{"i": [], "o": []}
{"i": [], "o": ["% ADCC of HIV - 1SF162 infected cells"]}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": ["ADCC activities", "ADCC activity"]}
{"i": [], "o": ["coated CEM cells", "ADCC activity"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["HIV - 1SF162 IC50 values"]}
{"i": [], "o": []}
{"i": [], "o": ["neutralization of HIV - 1JR - FL and signal intensity or antibody titer"]}
{"i": [], "o": []}
{"i": [], "o": ["ADCC activity and cross clade signal intensities or ELISA titers"]}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": ["cross clade ELISA titers", "ADCC activity"]}
{"i": [], "o": ["antibody signals or ELISA titers", "ADCC activity"]}
{"i": [], "o": ["antibody signals or ELISA titers .", "ADCC activity"]}
{"i": [], "o": []}
{"i": [], "o": ["% ADCCSF162 and IC50 HIV - 1JR - FL", "% ADCCSF162 and IC50 HIV - 1SF162"]}
{"i": [], "o": ["% ADCCSOSIP trimer and IC50 ' s or % ADCCJR - FL and IC50 ' s ."]}
{"i": [], "o": ["neutralization potency", "ADCC activity"]}
{"i": ["DNA prime / rAd5 boost vaccine"], "o": []}
{"i": ["multi - clade ( A , B , and C ) rAd5 vector boost"], "o": ["cross clade HIV - 1 specific antibody response"]}
{"i": [], "o": ["immune response", "antibody signal intensities"]}
{"i": [], "o": []}
{"i": [], "o": ["EnvA and EnvC subtype - specific antibody titers"]}
{"i": [], "o": ["EnvB specific baseline antibody signal levels"]}
{"i": [], "o": ["EnvB signal intensities"]}
{"i": ["maraviroc", "raltegravir ."], "o": []}
{"i": [], "o": ["EnvB specific antibody titers"]}
{"i": [], "o": ["EnvB intensities", "signal intensities"]}
{"i": ["DNA prime - rAd5 boost"], "o": ["EnvB antibody levels"]}
{"i": [], "o": ["pooled clade A , B , and C envelope antibody titers"]}
{"i": [], "o": ["cross clade antibody titers"]}
{"i": [], "o": ["antigen specific antibody levels"]}
{"i": [], "o": ["EnvB antibody responses"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["DNA prime - and envelope protein boost combinations"], "o": ["neutralizing antibody responses"]}
{"i": [], "o": ["low - titer neutralizing antibodies"]}
{"i": [], "o": []}
{"i": [], "o": ["IC50 values", "neutralization potency"]}
{"i": [], "o": ["IC50", "baseline IC50 values"]}
{"i": [], "o": ["EnvB specific antibody levels", "IC50 levels"]}
{"i": [], "o": ["antibody levels", "neutralization"]}
{"i": [], "o": []}
{"i": [], "o": ["IC50 levels"]}
{"i": [], "o": ["neutralization potency"]}
{"i": [], "o": ["HIV - 1JR - FL IC50 ' s"]}
{"i": [], "o": ["antibody neutralization potency"]}
{"i": [], "o": []}
{"i": ["ADCC"], "o": ["activity"]}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": []}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": ["antibody levels", "neutralization potency"]}
{"i": [], "o": []}
{"i": [], "o": ["antibody signals / titers and ADCC activity .", "HIV - 1 neutralization potency and ADCC activity"]}
{"i": [], "o": ["neutralization , antibody titers , and ADCC ."]}
{"i": ["DNA prime - rAd5 boost HIV vaccine"], "o": ["cross clade antibody titers"]}
{"i": [], "o": ["ADCC activity"]}
{"i": [], "o": ["neutralization potency or ADCC efficacy ."]}
{"i": [], "o": []}
{"i": ["EraMune 02"], "o": ["total CD4 + cell - associated HIV DNA"]}
{"i": [], "o": []}
{"i": [], "o": []}
